D3 Bio Showcases Transformative KRAS Pipeline at AACR 2026 Meeting in San Diego D3 Bio Inc will present groundbreaking data on its KRAS pipeline at AACR 2026, highlighting innovative therapies for cancer treatments.

D3 Bio Showcases Transformative KRAS Pipeline at AACR 2026 Meeting in San Diego #USA #San_Diego #oncology #D3_Bio #KRAS

D3 Bio Achieves FDA Clearance to Advance Innovative Cancer Trials with Two New IND Applications D3 Bio has received FDA clearance for two IND applications, paving the way for crucial cancer trials involving new therapeutics targeting KRAS mutations.

D3 Bio Achieves FDA Clearance to Advance Innovative Cancer Trials with Two New IND Applications #Shanghai #USA #KRAS_G12D #D3_Bio #elisrasib

D3 Bio Raises $108 Million to Propel Oncology Therapeutics Forward Globally D3 Bio has successfully raised $108 million in Series B financing, aimed at enhancing their global oncology drug development initiatives and advancing their promising clinical programs.

D3 Bio Raises $108 Million to Propel Oncology Therapeutics Forward Globally #Shanghai #USA #D3_Bio #oncology_therapeutics #elisrasib

D3 Bio's D3S-001 Receives Two Major FDA Designations for Treating KRAS G12C-Mutated Cancers D3 Bio, Inc. has announced that its drug D3S-001 has received FDA Breakthrough Therapy and Orphan Drug Designations for KRAS G12C-mutated cancers, highlighting its potential.

D3 Bio's D3S-001 Receives Two Major FDA Designations for Treating KRAS G12C-Mutated Cancers #Shanghai #United_States #KRAS_G12C #D3S-001 #D3_Bio